HR 238
Healthy Technology Act of 2025
TL;DR
Rep. David Schweikert (R-AZ-1) introduced the Healthy Technology Act of 2025, a very short bill that would let artificial intelligence and machine learning technology qualify as a 'practitioner' eligible to prescribe drugs, as long as it's authorized by state law and approved by the FDA. In practice, this would open the door for AI systems to legally prescribe medications in the United States for the first time.
How This Might Impact Your Business
Healthcare AI vendors (companies like clinical decision support tools, AI diagnostics platforms, and digital health startups) could pursue FDA authorization to have their systems prescribe medications directly, not just recommend them.
Telehealth companies could redesign workflows so AI handles prescribing for routine conditions (UTIs, contraception, chronic disease refills), reducing reliance on human clinicians.
Pharmacies and pharmacy benefit managers would need new systems to verify, process, and audit prescriptions written by AI 'practitioners' rather than licensed humans.
Pharmaceutical manufacturers may see faster prescribing cycles and new marketing channels aimed at AI systems rather than physicians.
Malpractice insurers, hospital systems, and health tech companies face unresolved liability questions: who is responsible when an AI prescriber causes harm?
State law still governs, meaning the change only takes effect in states that authorize AI prescribing, creating a patchwork rollout even if the bill passes.
The bill is only one page with no penalties, timelines, or compliance framework attached; the real rules would come from FDA approval processes and state medical boards.
What Should You Do
If you sell clinical AI, ask your regulatory team whether your product could be positioned for FDA authorization as a prescribing entity, and what evidence you'd need to generate now.
Healthcare operators should convene legal, compliance, and clinical leadership to draft a position on AI prescribing before state medical associations set the narrative.
Telehealth and pharmacy executives should model the economics of AI-driven prescribing for high-volume, low-complexity prescriptions to understand competitive exposure.
Ask your general counsel to review malpractice, product liability, and E&O insurance coverage for scenarios involving autonomous AI clinical decisions.
Track the bill through the House Energy and Commerce Committee; it has been introduced in prior sessions without advancing, so treat this as a signal to prepare, not an imminent mandate.
Who It Affects
Sponsors
Status Timeline
committee
Referred to the House Committee on Energy and Commerce.
January 7, 2025